


Australia's Lumonus launches strategic collaboration with cancer centre in US

April 9, 2026 | News

To advance radiation therapy treatment planning



Australia-based Lumonus, the company behind Lumonus AI, a platform for radiation oncology clinical workflow and automated treatment planning, has announced a collaboration with US-based Memorial Sloan Kettering Cancer Center (MSK), one of the world's premier cancer centres and a leader in radiation therapy treatment planning research.

Through this relationship, Lumonus will license and co-develop MSK's ECHO mathematical optimisation engine into the Lumonus platform and will invest in joint research focused on advancing automated radiation therapy treatment planning.

MSK's ECHO optimisation engine uses constraint-based mathematical methods to compute radiation therapy treatment plans from first principles. Developed over nearly a decade of clinical use and supported by an extensive body of peer-reviewed research, ECHO represents one of the most rigorously validated approaches to automated treatment planning in radiation oncology.

Tim Fox, Chief Product Officer at Lumonus said, *"Our strategic collaboration with MSK represents a decisive step forward. The next generation of planning automation requires a mathematically principled solver capable of consistently delivering the optimal plan, working in concert with intelligent review tools that capture the nuanced clinical judgement of physicians in real-world practice. Together with MSK, we are building the infrastructure to move automation from promising results to scaled, routine deployment."*